Rodilla, EnriqueSaura, AlbertoJiménez, IratxeMendizábal, AndreaPineda-Cantero, AraceliLorenzo-Hernández, ElizabethFidalgo-Montero, Maria del PilarFernandez López-Cuervo, JoaquínGil-Sánchez, RicardoRabadán-Pejenaute, ElisaAbella-Vázquez, LucyGiner-Galvañ, VicenteSolís-Marquínez, Marta NatayaBoixeda, Ramonde la Peña-Fernández, AndrésCarrasco-Sánchez, Francisco JavierGonzález-Moraleja, JulioTorres-Peña, José DavidGuisado-Espartero, María EstherEscobar-Sevilla, JoaquínGuzmán-García, MarcosMartín-Escalante, María DoloresMartínez-González, Ángel LuisCasas-Rojo, José ManuelGómez-Huelgas, Ricardo2021-06-112021-06-112020-09-28Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, et al. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. J Clin Med. 2020 Sep 28;9(10):3136.http://hdl.handle.net/10668/3366It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.enHypertensionCOVID-19Angiotensin-converting enzyme inhibitors (ACEIs)Angiotensin II receptor blockers (ARBs)All-cause mortalityHipertensiónInfecciones por coronavirusAntagonistas de receptores de angiotensinaInhibidores de la enzima convertidora de angiotensinaMedical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::HypertensionMedical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus InfectionsMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors::Angiotensin-Converting Enzyme InhibitorsMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors::Angiotensin-Converting Enzyme InhibitorsMedical Subject Headings::Health Care::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Vital Statistics::MortalityMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Hospital MortalityMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Cause of DeathMedical Subject Headings::Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::ComorbidityMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Cardiovascular Agents::Antihypertensive AgentsMedical Subject Headings::Geographical Locations::Geographic Locations::Europe::Spainresearch article32998337open access10.3390/jcm91031362077-0383PMC7650567